Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

Blood

Volumn 107, Issue 9, 2006, Pages 3733-3737

  Borgna Pignatti, Caterina ^a   Cappellini, Maria Domenica ^b   De Stefano, Piero ^b   Del Vecchio, Giovanni Carlo ^b   Forni, Gian Luca ^b   Gamberini, Maria Rita ^b   Ghilardi, Roberta ^b   Piga, Antonio ^b   Romeo, Maria Antonietta ^b   Zhao, Huaqing ^b   Cnaan, Avital ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; BACTERIAL ENDOCARDITIS; CHILD; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HEART DEATH; HEART DISEASE; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; STOMACH DISEASE; SURVIVAL RATE; THALASSEMIA MAJOR; TREATMENT DURATION;

EID: 33646407268     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2933     Document Type: Article

References (16)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
2. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood. 1991;77:2049-2053.
3. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med. 2002;139:50-58.
4. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-520.
5. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
6. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108: 305-312.
7. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336.
8. Breslow NE, Day NE. The analysis of case-control studies, No. 32. IARC Scientific Publications: Lyon, France, 1980.
9. Collet, D. Modelling Survival Data in Medical Research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC, 2003:160.
10. StatXact Version 6.0, Statistical Software for Exact Nonparametric Inference, User Manual, Cambridge, MA: 2003.
11. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;8653:27-30.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
13. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331: 574-578.
14. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85:393-400.
15. Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-407.
16. Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91: 295-300.